3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
11
Neoplasms
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Neuroendocrine Tumors
3
Glioma
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Fanconi Anemia, Complementation Group D1
2
Cholangiocarcinoma
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
SCLC,Extensive Stage
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Interventions
lutetium Lu 177 dotatate
2
Temozolomide
2
ONC206
2
Etoposide
2
Cyclophosphamide
2
Bevacizumab
2
olaparib
1
neratinib
1
ibrutinib
1
fenofibric acid
1
etoposide phosphate
1
brigatinib
1
Watchful Waiting
1
Thalidomide
1
Restraint, Physical
1
Radiotherapy
1
Radiation
1
Magnetic Resonance Spectroscopy
1
Linear Energy Transfer
1
Irinotecan
1
Elasticity Imaging Techniques
1
Cytarabine
1
Celecoxib
1
Automobiles
1
1-methyltryptophan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ependymoma
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled